Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1755617 | 1.00 | L3MBTL1 (0.55) | L3MBTL1RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL15048669 | 1.00 | L3MBTL1 (0.55) | L3MBTL1RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL14619698 | 0.83 | RAB9A (0.50) | L3MBTL1RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL14587454 | 0.79 | HCAR2 (0.52) | L3MBTL1RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL14587438 | 0.78 | RAB9A (0.46) | L3MBTL1RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL803250 | 0.76 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1LMNACYP2D6CYP2C19 | |
| SCHEMBL15286318 | 0.75 | RAB9A (0.47) | L3MBTL1RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL15286321 | 0.75 | RAB9A (0.47) | L3MBTL1RAB9ASMN1; SMN2NPC1MAOB | |
| SCHEMBL1395639 | 0.75 | ALDH1A1 (0.53) | L3MBTL1ALDH1A1LMNACYP2D6CYP2C19 | |
| SCHEMBL2880153 | 0.75 | L3MBTL1 (0.46) | L3MBTL1SMN1; SMN2NPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118257004-A | Method for screening molecular library from molecular library of DCL-ABPP | 华南理工大学 | 2024-06-28 | — | — | CN | claimed |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4658314-A1 | MAGNETIC HYDROGEL PARTICLES AND METHODS OF USE | The Regents of the University of California (US) | 2025-12-10 | — | — | EP | disclosed |
| CN-118267478-B | Application of agent for silencing or inhibiting LPCAT1 gene in induction of iron death of tumor cells | 中山大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-119192236-B | Serine hydrolase inhibitor and preparation method and application thereof | 西北农林科技大学深圳研究院 | 2025-03-11 | — | — | CN | disclosed |
| CN-119192236-A | Serine hydrolase inhibitor and preparation method and application thereof | 西北农林科技大学深圳研究院 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024163471-A1 | MAGNETIC HYDROGEL PARTICLES AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-118384290-A | Hybrid immunoglobulins containing non-peptide linkages | 生物分子控股有限责任公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118267478-A | Application of agent for silencing or inhibiting LPCAT1 gene in induction of iron death of tumor cells | 中山大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-118257004-A | Method for screening molecular library from molecular library of DCL-ABPP | 华南理工大学 | 2024-06-28 | — | — | CN | disclosed |
| CN-118257004-A | Method for screening molecular library from molecular library of DCL-ABPP | 华南理工大学 | 2024-06-28 | — | — | CN | disclosed |
| EP-4169944-A1 | PROCESS FOR PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220275108-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-09-01 | — | — | US | disclosed |
| EP-4039281-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3701971-B1 | COMPOUNDS USEFUL IN PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-2607361-A1 | Thiirane and michael acceptor compounds and their medical use | Ludwig-Maximilians-Universität München (DE) | 2013-06-26 | — | — | EP | disclosed |
| EP-2607361-A1 | Thiirane and michael acceptor compounds and their medical use | Ludwig-Maximilians-Universität München (DE) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275108-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, FCGR2A, VSIG8 | L3MBTL1 2238/4885RAB9A 3740/4885SMN1; SMN2 4483/4885 |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | FCGR2A, FCGR3B, CD74 | L3MBTL1 1181/4885RAB9A 3901/4885SMN1; SMN2 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.